Evidence map›Paper›PMID 39607525›Full record

ArticleJournal of gastrointestinal cancer2024

Immunohistochemical Expression of ROR2 in Gastrointestinal Stromal Tumor.

Asmaa Gaber Abdou, Mona Kandil, Moshira Abd El Wahed, Zeinab Elakabawy, Iman Loay, Hala Said El-Rebey

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of gastrointestinal cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Asmaa Gaber AbdouPathology Department, Faculty of Medicine, Menoufia University, Shebein Elkom, Egypt. asmaa_elsaidy@yahoo.com.
Mona KandilPathology Department, Faculty of Medicine, Menoufia University, Shebein Elkom, Egypt.
Moshira Abd El WahedPathology Department, Faculty of Medicine, Menoufia University, Shebein Elkom, Egypt.
Zeinab ElakabawyPathology Department, Faculty of Medicine, Menoufia University, Shebein Elkom, Egypt.
Iman LoayEgyptian National Cancer Institute, Cairo, Egypt.
Hala Said El-RebeyPathology Department, Faculty of Medicine, Menoufia University, Shebein Elkom, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors affecting the digestive tract, comprising approximately 0.1-3% of all gastrointestinal cancers. ROR2, a member of the receptor tyrosine kinase orphan receptor subfamily, functions as a signaling receptor for Wnt ligands. This study aims to assess the prognostic significance of ROR2 expression in GIST.

methodsA total of 56 paraffin-embedded blocks of GIST cases originating from different parts of the gastrointestinal tract (GIT) were included in this study. Immunohistochemistry was performed to detect ROR2 expression.

resultsROR2 expression was observed in 71.4% of GIST cases, and strong intensity of ROR2 staining was significantly associated with prolonged overall survival of GIST patients (p = 0.048). Furthermore, ROR2 positivity and the percentage of immunostaining showed an inverse correlation with tumor progression.

conclusionsGIST cases displaying ROR2 positivity exhibit a reduced likelihood of disease progression and demonstrate favorable prognostic characteristics.

Indexed as

Biomarkers, TumorGastrointestinal NeoplasmsGastrointestinal Stromal TumorsImmunohistochemistryReceptor Tyrosine Kinase-like Orphan ReceptorsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedPrognosisBiomarkers, TumorReceptor Tyrosine Kinase-like Orphan ReceptorsROR2 protein, humanGISTKI67PrognosisROR2

Identifiers

PMID39607525

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.